13.74
1.84 (15.46%)
| Penutupan Terdahulu | 11.90 |
| Buka | 11.92 |
| Jumlah Dagangan | 18,613,061 |
| Purata Dagangan (3B) | 8,984,172 |
| Modal Pasaran | 13,616,536,576 |
| Harga / Jualan (P/S) | 5.11 |
| Harga / Buku (P/B) | 6.56 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2025 |
| Margin Operasi (TTM) | -17,980.98% |
| EPS Cair (TTM) | -0.330 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -87.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.39% |
| Nisbah Semasa (MRQ) | 12.88 |
| Aliran Tunai Operasi (OCF TTM) | -341.58 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -208.35 M |
| Pulangan Atas Aset (ROA TTM) | -10.96% |
| Pulangan Atas Ekuiti (ROE TTM) | -13.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ASCLETIS-B | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.5 |
| Purata | 0.50 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ASCLETIS-B | 14 B | - | - | 6.56 |
| 3SBIO | 67 B | 0.82% | 27.19 | 3.88 |
| KEYMED BIO-B | 19 B | - | - | 4.95 |
| HAOHAI BIOTEC | 12 B | 3.41% | 14.58 | 1.00 |
| AKESO | 111 B | - | - | 15.36 |
| PHARMARON | 56 B | 0.92% | 22.04 | 2.39 |
|
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other regions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Value |
| % Dimiliki oleh Orang Dalam | 74.38% |
| % Dimiliki oleh Institusi | 0.74% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |